What happened with ACRV today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Acrivon Therapeutics seeks to match cancer patients with drugs most likely to work for them. Its proprietary AP3 platform measures how drugs change protein activity in cells and tumors, while its OncoSignature tests examine tumor samples to identify likely responders. This approach guides both drug development and patient selection for clinical trials, rather than relying only on genetic changes.
The business centers on two clinical-stage candidates: ACR-368, licensed from Lilly, and ACR-2316, developed internally. Acrivon has no approved products and has never generated revenue. It has funded operations mainly by raising capital from investors and needs additional funding to continue development. Potential future collaboration partners could pay licensing fees, milestone payments and research reimbursements; these are not established revenue streams. Its Lilly license requires milestone payments and royalties if specified development and sales conditions are met.
Future drug sales depend heavily on these candidates succeeding in trials and obtaining regulatory approval, and on the tests correctly identifying patients who respond. OncoSignature has not received regulatory approval. Where a drug needs a companion test for safe and effective use, FDA approval generally also requires the test to be approved or cleared.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Zentalis Pharmaceuticals, Inc. competes with Acrivon's ACR-2316 through azenosertib, an investigational cancer drug that blocks WEE1. Azenosertib's efficacy and safety results, including in platinum-resistant ovarian cancer, matter to the treatment competition Acrivon faces.
Aprea Therapeutics, Inc.'s APR-1051 competes with Acrivon's ACR-2316 as an investigational treatment for cancers that depend on WEE1. Aprea is developing APR-1051 as an oral drug, making its clinical progress a concrete program to watch alongside ACR-2316.
Schrodinger, Inc.'s SGR-3515 competes directly with Acrivon's ACR-2316: both are clinical-stage drugs that block WEE1 and PKMYT1 to treat solid tumors. Watch SGR-3515's clinical progress rather than software sales to drugmakers, industrial companies and research institutions, which also form a substantial part of Schrodinger's business.
Eli Lilly & Co. supplies the intellectual-property rights behind Acrivon's lead program ACR-368; in return, Acrivon may owe up to $168 million in development and commercial milestones plus royalties on sales. Lilly released its rights of first negotiation over reacquiring the program in July 2025, leaving Acrivon free to negotiate global or territorial partnerships and sublicenses.
Fed Interest Rate Decision
Acrivon Therapeutics earns interest on cash and investments that helps offset the costs of developing ACR-368 and its other cancer drugs, so the Fed’s rate decision matters through income on funds it reinvests.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates across the economy could lift interest earned as Acrivon reinvests its funds, adding income to help cover research and development costs.
If it comes in below expectations
Lower rates across the economy could reduce interest earned as Acrivon reinvests its funds, leaving less income to help cover research and development costs.
Schrodinger, Inc. earningsSDGR
Schrodinger, Inc.’s report will show whether its SGR-3515 clinical program is advancing against the overlapping tumor targets shared with Acrivon’s ACR-2316.
Focus on SGR-3515’s clinical progress, not Schrodinger’s software sales. Trial advancement or meaningful clinical data would show another drug targeting WEE1 and PKMYT1 moving forward, making the development competition for ACR-2316 more tangible. A setback would weaken that immediate comparison, but would not show that ACR-2316 works.
Acrivon Therapeutics, Inc. earningsThis company
Acrivon Therapeutics has no approved drugs or product sales, so its report will show whether cash use to advance its drug candidates remains consistent with the runway its funds can support.
Read cash used in operations alongside research-and-development spending, and check whether ACR-2316 trial activity continues and ACR-368 remains focused on endometrial cancer. Slower cash use with continued program work would support the company’s stated funding runway into the second quarter of 2027; faster cash use or stalled work would point to a possible need to raise funds sooner or slow development.
